A new class of medications, called PCSK9 inhibitors, are a powerful reducer of cholesterol. These medications are ideal for people with certain hereditary high cholesterol that places them at great risk for deadly heart attacks. Yet, health insurers have raised numerous bureaucratic barriers, preventing patients from getting these potentially life-saving medicine. And the reason is very clear: money. The PCSK9 inhibitors have a list price of $14,600 per year and likely 10 million Americans would be medically eligible for these medications. So insurers have put in place every trick (prior authorizations, hoops of multiple tests and extensive documentation in order to delay and deny reimbursing for thee medications). Finally, now some insurers and manufacturers are coming together to make PCSK9 inhibitors available to some qualified patients.